IR103 is a co-formulation of Remune and a novel synthetic toll-like receptor (TLR-9) agonist adjuvant, Amplivax. The company presented the results at the International Symposium on HIV & Emerging Infectious Diseases (ISHEID) in Toulon, France.
IR103 differs from currently available antiretroviral drug therapies in that it is an immune-based therapy designed to replenish and enhance key immune cells that have been destroyed by the virus, thus allowing stimulation of an HIV-infected individual's immune system to fight the virus.
“The early results for IR103 in this clinical study are encouraging,” said lead investigator, Dr Andrea Gori, of the Department of Internal Medicine and Surgery at San Paolo Hospital, University of Milan. “We can now proceed to further investigate the potential advance that IR103 may provide through its unique ability to actively stimulate an HIV patient's immune system to fight the virus.”